Article
Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia
10 Jul 2017
Abstract excerpt
BACKGROUND: Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. The relapse is postulated to be due to leukemia stem cells (LSCs), which are different from normal hematopoietic stem cells (HSCs). LIN28B is microRNA regulator and stem cell reprogramming factor....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
